5-Azacytidine Improves the Osteogenic Differentiation Potential of Aged Human Adipose-Derived Mesenchymal Stem Cells by DNA Demethylation

The therapeutic value of adipose-derived mesenchymal stem cells (Ad-MSCs) for bone regeneration is critically discussed. A possible reason for reduced osteogenic potential may be an age-related deterioration of the Ad-MSCs. In long term in vitro culture, epigenomic changes in DNA methylation are known to cause gene silencing, affecting stem cell growth as well as the differentiation potential. In this study, we observed an age-related decline in proliferation of primary human Ad-MSCs. Decreased Nanog, Oct4 and Lin28A and increased Sox2 gene-expression was accompanied by an impaired osteogenic differentiation potential of Ad-MSCs isolated from old donors (>60 a) as compared to Ad-MSCs isolated from younger donors (<45 a). 5-hydroxymethylcytosine (5 hmC) and 5-methylcytonsine (5 mC) distribution as well as TET gene expression were evaluated to assess the evidence of active DNA demethylation. We observed a decrease of 5 hmC in Ad-MSCs from older donors. Incubation of these cells with 5-Azacytidine induced proliferation and improved the osteogenic differentiation potential in these cells. The increase in AP activity and matrix mineralization was associated with an increased presence of 5 hmC as well as with an increased TET2 and TET3 gene expression. Our data show, for the first time, a decrease of DNA hydroxymethylation in Ad-MSCs which correlates with donor-age and that treatment with 5-Azacytidine provides an approach which could be used to rejuvenate Ad-MSCs from aged donors.

[1]  Seok-Goo Cho,et al.  Clinical applications of mesenchymal stem cells , 2013, The Korean journal of internal medicine.

[2]  Cristian Coarfa,et al.  SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. , 2013, Cell reports.

[3]  J. Hengstler,et al.  Decrease of Global Methylation Improves Significantly Hepatic Differentiation of Ad-MSCs: Possible Future Application for Urea Detoxification , 2013, Cell transplantation.

[4]  J. Henríquez,et al.  Control of osteogenesis by the canonical Wnt and BMP pathways in vivo , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.

[5]  V. Lunyak,et al.  Epigenetics: judge, jury and executioner of stem cell fate. , 2012, Epigenetics.

[6]  R. Pignolo,et al.  Impairment of osteoblast differentiation due to proliferation‐independent telomere dysfunction in mouse models of accelerated aging , 2012, Aging cell.

[7]  S. Hung,et al.  Oct4 and Nanog directly regulate Dnmt1 to maintain self-renewal and undifferentiated state in mesenchymal stem cells. , 2012, Molecular cell.

[8]  J. Bordeaux,et al.  Lin28 regulates HER2 and promotes malignancy through multiple mechanisms , 2012, Cell cycle.

[9]  Yongjun Wang,et al.  Over-expression of Sox2 in C3H10T1/2 cells inhibits osteoblast differentiation through Wnt and MAPK signalling pathways , 2012, International Orthopaedics.

[10]  Manel Esteller,et al.  Hot topics in epigenetic mechanisms of aging: 2011 , 2012, Aging cell.

[11]  K. Yamana,et al.  SP7 Inhibits Osteoblast Differentiation at a Late Stage in Mice , 2012, PloS one.

[12]  Avi Ma’ayan,et al.  Oct4 links multiple epigenetic pathways to the pluripotency network , 2011, Cell Research.

[13]  S. Kang,et al.  SOX2 has a crucial role in the lineage determination and proliferation of mesenchymal stem cells through Dickkopf-1 and c-MYC , 2011, Cell Death and Differentiation.

[14]  Y. H. Kim,et al.  Importance of Sox2 in maintenance of cell proliferation and multipotency of mesenchymal stem cells in low‐density culture , 2011, Cell proliferation.

[15]  J. Hare,et al.  Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. , 2011, Circulation research.

[16]  O. Abdel-Wahab,et al.  TET family proteins and their role in stem cell differentiation and transformation. , 2011, Cell stem cell.

[17]  S. Chandran,et al.  Lineage-specific distribution of high levels of genomic 5-hydroxymethylcytosine in mammalian development , 2011, Cell Research.

[18]  R. Oreffo,et al.  Skeletal tissue regeneration: current approaches, challenges, and novel reconstructive strategies for an aging population. , 2011, Tissue engineering. Part B, Reviews.

[19]  Yaojiong Wu,et al.  Epigenetic Dysregulation in Mesenchymal Stem Cell Aging and Spontaneous Differentiation , 2011, PLoS ONE.

[20]  Thomas A Einhorn,et al.  The biology of fracture healing. , 2011, Injury.

[21]  Ling Liu,et al.  Manifestations and mechanisms of stem cell aging , 2011, The Journal of cell biology.

[22]  Jennifer J Westendorf,et al.  Histone deacetylases in skeletal development and bone mass maintenance. , 2011, Gene.

[23]  Riitta Lahesmaa,et al.  Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. , 2011, Cell stem cell.

[24]  S. Dooley,et al.  TGF-β1 As Possible Link between Loss of Bone Mineral Density and Chronic Inflammation , 2010, PloS one.

[25]  Yi Zhang,et al.  Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification , 2010, Nature.

[26]  Reid F. Thompson,et al.  Tissue‐specific dysregulation of DNA methylation in aging , 2010, Aging cell.

[27]  W. Mutschler,et al.  Quantification of fluorescence intensity of labeled human mesenchymal stem cells and cell counting of unlabeled cells in phase-contrast imaging: an open-source-based algorithm. , 2010, Tissue engineering. Part C, Methods.

[28]  W. Deng,et al.  Switching cell fate: the remarkable rise of induced pluripotent stem cells and lineage reprogramming technologies. , 2010, Trends in biotechnology.

[29]  Sean J Morrison,et al.  Mechanisms of stem cell self-renewal. , 2009, Annual review of cell and developmental biology.

[30]  M. Miga,et al.  Regenerative Effects of Transplanted Mesenchymal Stem Cells in Fracture Healing , 2009, Stem cells.

[31]  Yingqun Huang,et al.  Lin28 modulates cell growth and associates with a subset of cell cycle regulator mRNAs in mouse embryonic stem cells. , 2009, RNA.

[32]  J. Snyder,et al.  Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294 , 2009, Nature Structural &Molecular Biology.

[33]  O. Lee,et al.  Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. , 2008, Gastroenterology.

[34]  E. Jones,et al.  Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies , 2008, Mechanisms of Ageing and Development.

[35]  Alexei A. Sharov,et al.  Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells , 2007, Nature Cell Biology.

[36]  L. Sowers,et al.  Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. , 2007, Cancer research.

[37]  Q. Han,et al.  [Application of mesenchymal stem cell in immunotherapy--review]. , 2005, Zhongguo shi yan xue ye xue za zhi.

[38]  T. Tollefsbol,et al.  Transcriptional control of the DNA methyltransferases is altered in aging and neoplastically-transformed human fibroblasts , 2003, Molecular and Cellular Biochemistry.

[39]  J. Miyazaki,et al.  Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells , 2000, Nature Genetics.

[40]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[41]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[42]  N. Nardi,et al.  Methodology, biology and clinical applications of mesenchymal stem cells. , 2009, Frontiers in bioscience.

[43]  J. Peltonen,et al.  [Fracture healing]. , 1985, Duodecim; laaketieteellinen aikakauskirja.